All In Biotech

Drug Trial Radar · NCT00490971

A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder

A Randomized, Double-Blind, Active- and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Extended-Release Paliperidone as Maintenance Treatment After an Acute Manic or Mixed Episode Associated With Bipolar I Disorder

Last checked: Nov 19, 2026Latest source record: Apr 15, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 768 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

768

Actual

Start

May 2006

Primary completion

Apr 2010

Study completion Apr 2010

Sponsor

Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Jun 25, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effectiveness and safety of oral extended-release (ER) paliperidone compared with placebo in the prevention of the recurrence of mood symptoms in patients with Bipolar I Disorder who initially respond to treatment of an acute manic or mixed episode with paliperidone ER. Olanzapine was included as an active control arm, although the study is not designed to allow for a direct comparison of olanzapine with paliperidone.

Conditions

  • Bipolar Disorder

Interventions

  • OlanzapineDrug

    Once daily in dose range of 5 to 20 mg/day for 15 weeks, then until recurrence

  • Paliperidone ERDrug

    Once daily in dose range of 3 to 12 mg/day for 15 weeks, then until recurrence

  • PlaceboDrug

    Once daily until recurrence (only after initial 15 weeks on paliperidone ER)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Recurrence of Any Mood Symptoms (Manic or Depressive) Associated With Bipolar I DisorderTime frame: Date of randomization into the maintenance phase until the first occurrence of recurrence of any symptoms or discontinuation from the study, assessed over a period of 41 months.

Locations

78 sites in 16 countries. Site status is shown where the registry gives one.

  • Site not named

    Scottsdale, Arizona

  • Site not named

    Riverside, California

  • Site not named

    San Diego, California

  • Site not named

    Jacksonville, Florida

  • Site not named

    Honolulu, Hawaii

  • Site not named

    Chicago, Illinois

  • Site not named

    Hoffman Estates, Illinois

  • Site not named

    Wichita, Kansas

  • Site not named

    New Orleans, Louisiana

  • Site not named

    Willingboro, New Jersey

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Lyndhurst, Ohio

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Arlington, Texas

  • Site not named

    Austin, Texas

  • Site not named

    Bellevue, Washington

  • Site not named

    Bulgaria, Bulgaria

  • Site not named

    Radnevo, Bulgaria

  • Site not named

    Sofia, Bulgaria

  • Site not named

    Baoding, China

  • Site not named

    Beijing, China

  • Site not named

    Guangzhou, China

  • Site not named

    Nanjing, China

  • Site not named

    Shanghai, China

  • Site not named

    Suzhou, China

  • Site not named

    Xi'an, China

  • Site not named

    San José, Costa Rica

  • Site not named

    Casablanca, France

  • Site not named

    Manouba, France

  • Site not named

    Berlin, Germany

  • Site not named

    Bochum, Germany

  • Site not named

    Chemnitz, Germany

  • Site not named

    Düsseldorf, Germany

  • Site not named

    Göttingen, Germany

  • Site not named

    Jena, Germany

  • Site not named

    Lübeck, Germany

  • Site not named

    Bangalore, India

  • Site not named

    Calicut, India

  • Site not named

    Coimbatore, India

  • Site not named

    Hyderabad, India

Showing 40 of 78 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.